在心脏骤停患者 (ICECAP) 试验中冷却时间对疗效的影响中,温度控制实践的变化
Rachel Beekman1, Sarah M Perman2, Christine Nguyen1
1Department of Neurology, Yale School of Medicine, New Haven, CT, United States.
Resuscitation
|September 15, 2024
概括
临床试验场所的温度控制实践有很大差异,影响神经保护. 标准化方法对于一致的患者结果和可靠的研究结果至关重要.
科学领域:
- 临界护理医学 临界护理医学
- 神经学 神经学
- 临床试验 临床试验
背景情况:
- 温度控制是一种复杂的干预措施,单个组件的协同作用不明.
- 优化温度控制参数对于最大限度地发挥其神经保护潜力至关重要.
研究的目的:
- 描述温度控制参数的变化,并确定早期启动的障碍.
- 评估与多中心临床试验中的温度控制相关的机构实践.
主要方法:
- 在ICECAP试验的主要研究人员 (NCT04217551) 中进行了一项横截面调查研究.
- 一项基于网络的23个问题的调查评估了温度控制实践,包括机构协议.
- 对开放式反应的定性分析和从ICECAP试验数据库中提取质量数据补充了调查结果.
主要成果:
- 75%的地点接受了调查,其中80%的地点有机构温度控制协议.
- 在诱导和启动时间期间使用神经肌肉阻塞 (NMB) 观察到显著的变化.
- 关于早期温度控制启动的临床虚无主义是最常见的障碍 (62.5%).
结论:
- 在临床试验地点之间,在早期启动温度控制的资源,方法和障碍方面存在很大差异.
- 标准化高质量的温度控制是确保对临床试验结果的准确解释的优先事项.
相关概念视频
01:29Decreased Body Temperature
602
A decreased body temperature can occur in patients with hypothermia and frostbite. Heat loss with extended cold exposure overpowers the body's ability to create heat, resulting in hypothermia. Core temperature readings help classify hypothermia. Mild hypothermia is temperatures between 32 °C (89.6 °F) and 35°C (95 °F) and is caused by impaired thermoregulation. Moderate hypothermia is temperatures between 28 C (82.4 °F) and 32 °C (89.6 °F) caused by...
602
01:22Methods of reducing fever
649
The signs and symptoms of fever include hot and dry skin, flushed face, thirst, muscle aches, anorexia, headache, tachycardia, tachypnea, and fatigue. Elevated body temperature is reduced using two methods: pharmacological and nonpharmacological. Proper identification and treatment of the root cause of a fever is of utmost importance.
Pharmacological Methods of Reducing Fever:
Pharmacological Methods of Reducing Fever:
649
01:28Factors Affecting Body Temperature
4.0K
As a nurse, it is vital to understand the factors affecting body temperature to monitor variations and effectively evaluate deviations from regular.
Factors may include:
Factors may include:
4.0K